19 June 2013
Keywords: xoma, drops, cd5, plus, graft-versus-host, disease, announced
Article | 09 January 1995
Xoma has announced that it has discontinued development of its CD5 Plus
antibody product for patients with graft-versus-host disease. The
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
9 January 1995
16 January 1995
18 June 2013
© 2013 thepharmaletter.com